{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-240757","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.029401+00:00","generated_at":"2026-05-30T12:08:00.190661+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"XOMA Royalty acquires 50% of Twist Bioscience's royalty/milestone economics for $15M","bullets":["Acquired 50% economic interest in milestones/royalties from Twist's 60+ early-stage programs across 30 partners for $15M upfront.","XOMA's portfolio now exceeds 100 assets, spanning commercial to pre-clinical programs.","Twist's Biopharma Solutions business unit yields future payments under biopharma services agreements.","Chief Investment Officer Brad Sitko cites potential for superior risk-adjusted returns.","Gibson, Dunn & Crutcher served as XOMA's legal advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-240757","json":"https://secwatch.observer/filing/0001193125-24-240757.json","markdown":"https://secwatch.observer/filing/0001193125-24-240757.md","text":"https://secwatch.observer/filing/0001193125-24-240757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312524240757/0001193125-24-240757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312524240757/d826403d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:08:00.190661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}